Surveillance de l'innocuité du tofacitinib après sa mise sur le marché sur une période de 9 ans chez des patients atteints de rhumatisme psoriasique et de polyarthrite rhumatoïde
Rheumatol Ther. 2023;10(5):1255–1276 doi: 10.1007/s40744-023-00576-8
The data gathered in this post-marketing surveillance study aligned with the previously established safety profile of tofacitinib, and reports were found to have consistent safety profiles in the treatment of both patient with PsA and RA. However, the results of this study should be interpreted considering the limitations of post-marketing surveillance studies.